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Identity 
Other names: FETA, HPAFP 
HGNC (Hugo): AFP 
Location: 4q13.3 
Local order: AFP belongs to the family of albumin 
genes together with serum albumin (ALB), group-
specific component/vitamin D-binding protein (GC) 
and afamin/alpha-albumin (AFM). All genes of this 
family are localized on the long arm of chromosome 4 
and are proposed to originate from common 
predecessor. ALB, AFP and AFM located at the same 
chromosome locus consequently are proposed to be 
cooperatively regulated (Lazarevich, 2000). 
Note  
25037 bases. AFP was described as a major fetal serum 
protein absent in normal adult serum. Later dramatic 
increase of AFP level was revealed in serum of mice 
and humans with hepatocellular carcinoma, 
hepatoblastoma, germ cell tumors and gastrointestinal 
carcinomas (Abelev et al., 1963; Abelev, 1971). These 
findings allowed to classify AFP that is expressed in 
embryo, downregulated after birth and reactivated in 
cancer, as onco-embryonic marker. Alterations of AFP 
level in blood serum are widely used in diagnostics of 
several types of epithelial cancers and abnormalities of 
prenatal development (Abelev and Eraiser, 1999). 
DNA/RNA 
Description 
Human AFP gene consists of 15 exons and 14 introns, 
15th exon is noncoding. Like other albumin genes it is 
proposed to originate from common predecessor that 
arose as a result of triplication of a primary ancestral 
gene. 7 kb 5'-upstream regulatory region controls stage- 
and tissue-specific expression of AFP. 
Transcription 
AFP expression is controlled mainly on the 
transcriptional level.  
It is regulated by tissue-specific promoter, three 
independent enhancers, and a silencer that is at leas
partially responsible for AFP gene repression after birth 
(Spear, 1999).  
AFP gene expression is regulated by complex network 
of transcriptional regulators such as oncogenes (c-my , 
c-fos, c-jun), p53 family members, nuclear receptors 
(glucocorticoid and retinoid receptors, HNF4α, FTF), 
hepatocyte nuclear factors (HNF1, FoxA, C/EBP 
families), zinc-finger repressors (Zhx2, Zbtb20) and 
ubiquitous factors (NF-1, Sp-1) (Lazarevich, 2000; 
Peterson et al., 2011). 
 
Albumin genes cluster. S - silencer; P - promoter; E1, E2, E3 - minimal enhancers of AFP gene; E - albumin enhancer. Tissue-specific 
AFP enhancers located between ALB and AFP genes can modulate transcriptional activities of both promoters. Arrows indicates start 
and direction of transcription 
 
. 
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Full length AFP transcript (NM_001134, 2032 bp in 
humans) is predominant in fetal liver. Shorter mRNAs 
about 1.7, 1.4, and 1.0 kb were reported in mammalian 
fetal or regenerating liver and carcinoma cell cultures 
(Lemire and Fausto, 1991).  
In human hematopoietic progenitor cells the existence 
of two variant AFP forms originated by replacing of 
exon 1 with one or two alternative exons located in 5-
untranslated region is proposed (Kubota et al., 2002). 
AFP isoform lacking exon 1 was identified in ovarian 
yolk sac tumor (Fukasawa et al., 2005). 
The functional role of shortened AFP transcription 





AFP is translated as a major 609 amino acids precursor 
form (P02771) which is processed into a mature 70-kD 
glycoprotein consisting of 591 amino acids with 3-5% 
of carbohydrate residues.  
AFP consists of three homologous functional domains 
and have characteristic pattern of cysteine residue 
folded into layers through disulfide bridging. Single 
carbohydrate chain is linked through asparagine 233.  
AFP microheterogeneity is mainly due to different 
length and structure of carbohydrate moieties, the 
extent of their sialylation and fucosylation 
(Mizejewski, 2001). Shorter isoforms truncated at N-
terminal amino acids sequence are also described 
(Fukasawa et al., 2005).  
Based on different affinity towards several lectins 
(Concanavalin A, Lens culinaris agglutinin (LCA), 
erythroagglutinating phytohemagglutinin) AFP variants 
can be separated into several groups of glycoforms.  
Specifically, according to LCA reactivity on affinity 
electrophoresis representing the degree of its 
fucosylation, AFP can be divided into three fractions, 
AFP-L1, AFP-L2, and AFP-L3. AFP-L1 that does not 
react with LCA is characteristics for non-malignant 
liver diseases, AFP-L2 (intermediate reactive) is 
detected in maternal serum during pregnancy and 
patients with yolk sac tumors, highly LCA-reactive 
AFP-L3 fraction is expressed by malignant liver tumors 
(Mizejewski, 2001; Debruyne and Delanghe, 2008). 
Expression 
Normally AFP is produced by visceral endoderm of 
yolk sac, embryonic liver and in lesser extent in fetal 
gut and kidney.  
AFP is secreted into blood serum, reaching maximum 
concentration (about 3 mg/ml) at 12-16 weeks of 
embryonic development.  
In the first weeks after birth AFP synthesis decrease 
dramatically.  
In adults AFP levels in circulation is lower than 10-20 
ng/ml. AFP reactivation in adults may result from liver 
regeneration, noncancerous liver diseases such as viral 
hepatitis or cirrhosis, primary liver or germ cell tumors 
and to lesser extent several forms of other epithelial 




Like other proteins of albumin family AFP possesses 
transport function binding heavy metals, fatty acids, 
bilirubin, retinoids, steroids, divalent cations, various 
organic drugs and environmental agents (Deutsch, 
1991; Mizejewski, 2001).  
At least in rodents AFP demonstrate estrogen-binding 
properties indicating that in developing embryo 
circulating AFP could act as neuroprotective estrogen-
neutralizing protein. Experiments on AFP knockout 
mice proved essential role of AFP in the control of 
female fertility (De Mees et al., 2006).  
Compared to ALB, AFP exhibits enhanced affinity to 
polyunsaturated fatty acids that denotes its possible role 
in maternal-to-fetal circulation through the placenta.  
AFP is proposed to be involved in the control of 
proliferation, embryonic differentiation, regulation of 
osmotic pressure, protection of developing fetus from 
maternal immune system (Mizejewski, 2001; 
Mizejewski, 2007).  
However the precise mechanisms and universality of 
these functions need to be clarified by further 
investigations. 
Homology 
AFP possesses amino acid sequence homology to other 
members of albumin family - ALB, AFM and GC. All 
the albumin proteins are composed of three 
homologous albumin domains with similar cysteine 
disulfide bridge clusters (Mizejewski, 2001). 
Mutations 
Germinal 
In AFP coding region several SNP variants with 
unknown clinical significance are described.  
SNPs in AFP promoter region are associated with 
hereditary persistence of alpha-fetoprotein (HPAFP) - 
rare autosomal dominantly inherited benign disorder 
with elevated serum AFP levels (>20 ng/mL) not 
associated with clinical disability. HPAFP is due to 
119G>A and 55C>A substitutions in distal and 
proximal HNF1 binding sites in AFP promoter which 
increase affinity of HNF1 transcription factor bindg 
(Alj et al., 2004). 
Somatic 
In genome databases very rare somatic mutations of 
AFP with unclear clinical significance are reported. 
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Implicated in 
Hepatocellular carcinoma (HCC) 
Disease 
Hepatocellular carcinoma is the most prevalent liver 
tumor and fifth most frequent cancer worldwide. The 
major risk factors for development of HCC are chronic 
infection with hepatitis B or C viruses, prolonged 
exposure to hepatocarcinogens and cirrhosis (Bosch et 
al., 1999). HCCs that are often diagnosed at the 
advanced stages and are highly resistant to 
conventional chemotherapy have very poor prognosis 
(about 7% 5-year survival). 
Expression and secretion of AFP reversibly repressed 
in adult liver is dramatically induced in transformed 
hepatocytes (Abelev et al., 1963; Abelev, 1971).  
Elevation of serum AFP is widely used as diagnostics 
marker for HCC. Sensitivity and specificity of the test 
depends significantly on the cut-off range (typically it 
varies between 20-50 ng/ml and may depend from age, 
geographical population and HCC etyology) (Debruyne 
and Delanghe, 2008).  
High (>500 ng/ml) serum AFP level is described in 
>80% of children and about 70% of adults with HCC 
and distinguishes primary liver cancer from non-
malignant liver disease (see below). Small highly 
differentiated HCCs are often AFP-negative. On the 
other hand, low AFP levels are also described in highly 
dedifferentiated anaplastic tumors (probably due to 
extinction of its tissue-specific transcriptional 
regulators). Specificity and sensitivity of HCC 
differentiation diagnosis can be enhanced through 
detection of LCA-reactive glycoform of AFP (AFP-L3) 
which is preferably expressed in malignant liver tumors 
(Debruyne and Delanghe, 2008). 
Prognosis 
Currently AFP serum test is conventionally used in 
early diagnostics of HCC especially in high risk 
groups. Serial measurement of serum AFP level is 
useful for monitoring the treatment response in HCC 
patients after surgical resection, chemotherapy or 
orthotopic liver transplantation. High proportion of
LCA-reactive AFP glycoform (AFP-L3 fraction) is 
associated with more malignant phenotype and poor 
prognosis of HCC (Debruyne and Delanghe, 2008; 
Sturgeon et al., 2010). 
Hepatoblastoma 
Note 
The most common type of pediatric liver cancer that 
phenotypically is highly similar to hepatoblasts - 
immature parenchimal cells of embryonic liver that 
give rise to hepatocytes and cholangiocytes. Like 
hepatoblasts, hepatoblastoma cells produce extremely 
high levels of AFP. In >80% of affected patients serum 




In majority of cases hepatoblastoma is highly sensitive 
to chemotherapy with cytostatic and cytotoxic drugs. 
Thus, combination of surgical treatment with 
neoadjuvant chemotherapy critically improved 5-year 
survival rate up to 75%.  
Increase of serum AFP level in children is a sensitive 
marker for diagnosis and posttreatment monitoring of 
hepatoblastoma (Herzog et al., 2000). Correlation of 
pretreatment AFP level with clinical outcome is not 
clear. 
Germ cell tumors 
Disease 
Germ cell tumors integrate several types of testis and
ovary cancers originating from different cell types. 
Elevation of serum AFP levels is associated with 
embryonic carcinoma (derived from undifferentiated 
pluripotent early embryonic cells) and teratocarcinoma 
(tumors containing both embryonic carcinoma cells and
more or less differentiated somatic tissue elements) as 
well as yolk sac (originating from endodermal 
component of fetal yolk sac) tumors. Seminoma and 
dysgerminoma, originating from germinal cells, as well 
as stromal and surface epithelium derived germ cell 
tumors are AFP negative (Abelev and Eraiser, 1999). 
Prognosis 
Due to sensitivity of germ cell tumors to cisplatin-
based chemotherapy even metastatic nonseminomatous 
germ cell tumors are highly curable with overall cure 
rates >80%. Pretreatment serum concentrations of AFP, 
human chorionic gonadotropin (HCG, see below), and 
lactate dehydrogenase are approved to be independent 
prognostic factors for patients with metastatic 
nonseminomatous germ cell tumors (International 
Germ Cell Cancer Collaborative Group, 1997). 
Oncogenesis 
Yolk sac is responsible for serum protein production at 
the outset of embryonic development. Accordingly the
forms of germ cell tumors containing embryonic and 
yolk sac elements (yolk sac tumors, embryonic 
carcinoma and teratocarcinoma) are characterized by 
increased AFP levels. Trophoblast elements of 
embryonic carcinoma and teratocarcinoma also 
produce elevated levels of HCG. In >80% of yolk sac
tumors and embryonic carcinomas serum AFP levels 
are elevated up to 1000 ng/ml (Abelev and Eraiser, 
1999). Combination of AFP and HCG is highly specific 
for differential diagnosis, choice of treatment strategy 
and monitoring of different forms of germ cell tumors. 
Various cancer 
Disease 
Increase of serum AFP level was also reported in 
several cases of gastric, biliary tract, pancreatic, lung, 
breast, renal, colorectal cancer. In majority of cases 
serum AFP level was <50 ng/ml (Kew, 1974; Abelev 
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and Eraiser, 1999). No association with liver 
metastases was described. 
Non-malignant liver diseases 
Disease 
Acute viral hepatitis, alcohol or drug-induced liver 
damage, cirrhosis, acute liver failure, states associated 
with liver regeneration. In the majority of hepatitis and 
cirrhosis cases serum AFP level is lower than 50 ng/ml 
while about 15% of patients demonstrate moderate 
AFP levels (>500 ng/ml). AFP produced by 
nonmalignant hepatocytes can be distinguished from 
that of HCC origin by its low ability to bind Lens 
culinaris lectin (AFP-L1 glycoform). Together with 
AFP elevation level this property is used for 
differentiation diagnosis of HCC and non-malignant 
liver diseases (Abelev and Eraiser, 1999). 
Prognosis 
In patients with acute liver failure high serum AFP 
concentration does not predict an improved outcome, 
while post-therapy rise of AFP values is associated 
with favourable prognosis (Schiodt et al., 2006). 
Abnormalities of fetus development and 
pregnancy disorders 
Note 
During pregnancy AFP synthesized in the yolk sac of 
the fetus enters the amniotic fluid through placenta and 
reaches the maternal circulation. AFP level in maternal 
serum at second-trimester is used as a diagnostic 
marker of developmental abnormalities of fetus. 
Disease 
Decreased AFP levels in maternal serum or amniotic 
fluid signify the chromosomal abnormalities of fetus 
such as Down's syndrome and trisomy 18. High levels 
of AFP indicate increased risk for neural tube defects 
such as spina bifida and anencephalopaty. Abnormal 
AFP level can also indicate other fetal defects or 
obstetric complications (Mizejewski, 2007). 
Hereditary disoders 
Disease 
Type I hereditary tyrosinemia is autosomal recessive 
disorder manifested in young infants by severe liver 
disease, renal tubular dysfunction, growth failure and 
rickets. Hereditary tyrosinemia results from deficiency 
of fumarylacetoacetate hydrolase (FAH), the last 
enzyme of tyrosine degradation. Severe liver disease 
increases the risk of HCC development. In patients 
newly diagnosed with hereditary tyrosinemia serum 
AFP levels are very high (up to 100,000 ng/ml), 
decreasing after treatment with nitisinone. Monitoring 
of AFP level is used to evaluate the risk of HCC in 
hereditary tyrosinemia patients. 
Ataxia telangiectasia is rare, autosomal recessive 
disorder of childhood caused by a defect in the ATM 
gene encoding serine/threonine protein kinase involved  
in DNA damage response and control of chromosome 
stability. Ataxia telangiectasia is manifested by 
cerebellar degeneration, dilation of the blood vessels, 
immunodeficiency, growth retardation, chromosomal 
instability, predisposition to cancer. Approximately 
95% of patients with ataxia-telangiectasia demonstrate 
stable elevation of serum AFP in childhood increasing 
slowly over time. Molecular basis of this correlation is 
not clear. 
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